Sana Biotechnology Inc (SANA)
8.55
-0.72
(-7.77%)
USD |
NASDAQ |
May 16, 16:00
8.545
0.00 (0.00%)
Pre-Market: 20:00
Sana Biotechnology Cash from Investing (Quarterly): -77.23M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -77.23M |
| December 31, 2023 | 15.31M |
| September 30, 2023 | 51.35M |
| June 30, 2023 | 42.63M |
| March 31, 2023 | 62.73M |
| December 31, 2022 | 88.43M |
| September 30, 2022 | 31.86M |
| June 30, 2022 | 77.73M |
| March 31, 2022 | 12.54M |
| Date | Value |
|---|---|
| December 31, 2021 | -73.66M |
| September 30, 2021 | -185.90M |
| June 30, 2021 | -35.32M |
| March 31, 2021 | 49.09M |
| December 31, 2020 | 13.04M |
| September 30, 2020 | -268.31M |
| June 30, 2020 | -36.47M |
| March 31, 2020 | 39.18M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-268.31M
Minimum
Sep 2020
88.43M
Maximum
Dec 2022
-11.35M
Average
15.31M
Median
Dec 2023
Cash from Investing (Quarterly) Benchmarks
| Rocket Pharmaceuticals Inc | 35.03M |
| Solid Biosciences Inc | 45.30M |
| Dyne Therapeutics Inc | -179.84M |
| Taysha Gene Therapies Inc | -0.14M |
| Tenaya Therapeutics Inc | -4.489M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -65.63M |
| Cash from Financing (Quarterly) | 186.40M |
| Free Cash Flow | -273.64M |
| Free Cash Flow Per Share (Quarterly) | -0.375 |
| Free Cash Flow Yield | -15.85% |